Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 453,632 |
|
|||||
| News | - | ||||||
| Day High | 3.7489 | Low High |
|||||
| Day Low | 3.48 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| AC Immune SA | ACIU | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.21 | 6.09% | 3.66 | 14:11:20 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.58 | 3.48 | 3.7489 | 3.45 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,173 | 453,632 | $ 3.64 | $ 1,649,285 | - | 1.90 - 5.14 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 14:11:47 | 90 | $ 3.675 | USD |
AC Immune SA Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 363.06M | 99.20M | - | 3.94M | -70.75M | -0.71 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
AC Immune News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ACIU Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.50 | 3.7489 | 3.05 | 3.31 | 438,648 | 0.16 | 4.57% |
| 1 Month | 2.31 | 3.7489 | 2.25 | 3.29 | 2,038,802 | 1.35 | 58.44% |
| 3 Months | 3.88 | 4.03 | 2.25 | 3.22 | 829,269 | -0.22 | -5.67% |
| 6 Months | 3.05 | 5.14 | 2.25 | 3.32 | 470,561 | 0.61 | 20.00% |
| 1 Year | 2.11 | 5.14 | 1.90 | 3.31 | 496,141 | 1.55 | 73.46% |
| 3 Years | 6.31 | 12.61 | 1.68 | 5.50 | 454,776 | -2.65 | -42.00% |
| 5 Years | 4.87 | 14.89 | 1.68 | 6.18 | 423,060 | -1.21 | -24.85% |
AC Immune Description
| AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. |
